Investigating how genetic factors affect immune responses in lung cancer treatment
Official title: Human leukocyte antigen and immune response in non-small cell lung cancer: A multi-omics approach
Funded at Harvard School of Public Health · NIH-11035860 · Data updated 2026-11-12
This study is looking at how certain genes in your immune system might affect how well you respond to cancer treatments if you have non-small cell lung cancer, with the goal of finding ways to personalize your treatment for better results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $127,629 |
| NIH project number | 1K99CA297010-01 |
| Project ID | NIH-11035860 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing treatment with immune checkpoint inhibitors.
✕Less likely to help
Patients with other types of lung cancer or those who are not eligible for immune checkpoint inhibitor therapy may not benefit from this research.
What this research studies
This research focuses on understanding how variations in human leukocyte antigen (HLA) genes influence the immune response to cancer therapies in patients with non-small cell lung cancer (NSCLC). By analyzing a large dataset that includes genetic, tumor, and clinical information, the study aims to identify new biomarkers that can predict which patients are likely to benefit from immune checkpoint inhibitors. The approach combines advanced statistical techniques and machine learning to uncover the complex interactions between genetics and immune response. Patients may have their genetic information analyzed to help tailor more effective treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promise in using genetic markers to predict responses to cancer therapies, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Harvard School of Public Health
Boston, United States Active
Researchers
- Principal investigator: Wang, Xinan — Harvard School of Public Health
- Study coordinator: Wang, Xinan
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.